PriceTargets.com logo

Pulmonx - LUNG Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.83
  • Forecasted Upside: 117.49%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.28 As of 04/26/2024 06:12 PM ET
▼ -0.02 (-0.27%)

This chart shows the closing price for LUNG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pulmonx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LUNG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LUNG

Analyst Price Target is $15.83
▲ +117.49% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Pulmonx in the last 3 months. The average price target is $15.83, with a high forecast of $18.00 and a low forecast of $12.00. The average price target represents a 117.49% upside from the last price of $7.28.

This chart shows the closing price for LUNG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Pulmonx. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$17.00Low
2/23/2024CitigroupBoost TargetBuy ➝ Buy$16.00 ➝ $17.00Low
2/23/2024Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$16.00 ➝ $14.00Low
2/22/2024Piper SandlerBoost TargetOverweight ➝ Overweight$13.00 ➝ $17.00Low
2/22/2024Stifel NicolausBoost TargetBuy ➝ Buy$15.00 ➝ $17.00Low
2/22/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$15.00 ➝ $16.00Low
10/31/2023Piper SandlerLower TargetOverweight ➝ Overweight$17.00 ➝ $13.00Low
10/31/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$20.00 ➝ $12.00Low
9/5/2023Craig HallumInitiated CoverageBuy$18.00Low
8/3/2023Piper SandlerBoost TargetOverweight ➝ Overweight$15.00 ➝ $17.00Low
7/10/2023CitigroupBoost Target$14.00 ➝ $16.00Low
5/3/2023Piper SandlerBoost Target$13.00 ➝ $15.00Low
4/3/2023CitigroupBoost TargetBuy$12.00 ➝ $13.00Low
2/27/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$10.00 ➝ $15.00Low
2/24/2023CitigroupBoost TargetBuy$10.00 ➝ $12.00Low
2/23/2023Canaccord Genuity GroupBoost TargetBuy$18.00 ➝ $20.00Low
2/23/2023Morgan StanleyBoost TargetEqual Weight$9.50 ➝ $11.00Low
1/6/2023Morgan StanleyLower TargetEqual Weight$14.00 ➝ $9.50Low
1/3/2023Bank of AmericaDowngradeNeutral ➝ Underperform$8.00Low
12/12/2022Wells Fargo & CompanyLower TargetEqual Weight$13.50 ➝ $6.00Low
12/12/2022CitigroupUpgradeNeutral ➝ Buy$14.00 ➝ $10.00Low
11/7/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $14.00Low
11/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$31.00 ➝ $16.00Low
11/4/2022Piper SandlerLower TargetOverweight$25.00 ➝ $13.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $19.00Low
8/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$34.00 ➝ $31.00Low
8/4/2022Morgan StanleyBoost TargetEqual Weight$19.00 ➝ $21.00N/A
8/3/2022Piper SandlerLower TargetOverweight$37.00 ➝ $25.00Low
7/18/2022Stifel NicolausLower Target$32.00 ➝ $20.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$30.00 ➝ $19.00Low
7/11/2022CitigroupDowngradeBuy ➝ Neutral$23.00 ➝ $19.00N/A
5/17/2022CitigroupLower Target$32.00 ➝ $23.00N/A
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral$28.00Medium
2/28/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$53.00 ➝ $34.00High
2/25/2022Morgan StanleyLower TargetEqual Weight$37.00 ➝ $30.00High
2/24/2022Wells Fargo & CompanyLower TargetEqual Weight$55.00 ➝ $27.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$48.00 ➝ $37.00Medium
12/8/2021Piper SandlerUpgradeNeutral ➝ Overweight$45.00High
11/3/2021Wells Fargo & CompanyLower TargetEqual Weight$56.00 ➝ $55.00High
11/2/2021Piper SandlerLower TargetNeutral$47.00 ➝ $45.00High
4/1/2021CitigroupInitiated CoverageBuy$60.00Low
3/25/2021Piper SandlerInitiated CoverageNeutral$50.00High
3/10/2021Bank of AmericaUpgradeNeutral ➝ Buy$72.00High
3/3/2021Wells Fargo & CompanyBoost Target$46.00 ➝ $54.00Medium
3/3/2021Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $53.00High
1/4/2021Bank of AmericaDowngradeBuy ➝ NeutralN/A
12/15/2020Morgan StanleyBoost TargetEqual Weight$46.00 ➝ $52.00Medium
11/11/2020Morgan StanleyBoost TargetEqual Weight$44.00 ➝ $46.00High
10/26/2020Bank of AmericaInitiated CoverageBuy$50.00Medium
10/26/2020Morgan StanleyInitiated CoverageEqual Weight$44.00Low
10/26/2020Stifel NicolausInitiated CoverageBuy$50.00Low
10/26/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$46.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 7 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/26/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Pulmonx logo
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $7.28
Low: $7.26
High: $7.49

50 Day Range

MA: $9.20
Low: $7.30
High: $14.50

52 Week Range

Now: $7.28
Low: $7.11
High: $14.84

Volume

112,627 shs

Average Volume

499,297 shs

Market Capitalization

$280.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulmonx?

The following Wall Street analysts have issued research reports on Pulmonx in the last year: Canaccord Genuity Group Inc., Citigroup Inc., Craig Hallum, Piper Sandler, Stifel Nicolaus, and Wells Fargo & Company.
View the latest analyst ratings for LUNG.

What is the current price target for Pulmonx?

6 Wall Street analysts have set twelve-month price targets for Pulmonx in the last year. Their average twelve-month price target is $15.83, suggesting a possible upside of 116.9%. Craig Hallum has the highest price target set, predicting LUNG will reach $18.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $12.00 for Pulmonx in the next year.
View the latest price targets for LUNG.

What is the current consensus analyst rating for Pulmonx?

Pulmonx currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LUNG.

What other companies compete with Pulmonx?

Other companies that are similar to Pulmonx include Sight Sciences, Cerus, CVRx, Lyra Therapeutics and Fractyl Health. Learn More about companies similar to Pulmonx.

How do I contact Pulmonx's investor relations team?

The company's listed phone number is 1-650-364-0400 and its investor relations email address is [email protected]. The official website for Pulmonx is pulmonx.com. Learn More about contacing Pulmonx investor relations.